Arrowstreet Capital
CTKB icon

Arrowstreet Capital’s Cytek Biosciences CTKB Stock Holding History

Arrowstreet Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
319,909
-41,768
-12% -$197K ﹤0.01% 1476
2025
Q4 		$1.83M Buy
361,677
+387
+0.1% +$1.8K ﹤0.01% 1434
2025
Q3 		$1.25M Buy
361,290
+217,038
+150% +$815K ﹤0.01% 1547
2025
Q2 		$490K Buy
144,252
+96,098
+200% +$320K ﹤0.01% 1752
2025
Q1 		$193K Buy
+48,154
New +$250K ﹤0.01% 1743

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital's CTKB Position: Q1 2026 in Review

Arrowstreet Capital reduced its Cytek Biosciences (CTKB) stake by 12% in Q1 2026, selling an estimated $197K and leaving 319,909 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Arrowstreet Capital first reported a position in CTKB in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.83M in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Arrowstreet Capital held 319,909 shares of Cytek Biosciences worth $1.4M as of Q1 2026.
  • Arrowstreet Capital sold 41,768 Cytek Biosciences shares in Q1 2026, an estimated $197K.
  • Cytek Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1476 holding.
  • Arrowstreet Capital first reported a position in Cytek Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Arrowstreet Capital's Cytek Biosciences position peaked at $1.83M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.